Clinical trial · Observational
Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)
Atypical Lesions of the Breast: Close Observation vs. Excision
NCT01925586CI-TRIAL-00036777ALCOVEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to look at whether it is feasible to observe women with atypical ductal hyperplasia (ADH) of the breast, or whether surgical excision is necessary.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Atypical Ductal Hyperplasia (ADH) of the Breast | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Findings of palpable mass or imaging abnormality (increase in size or in the amount of calcifications)
- timeFrame
- 5 years
- description
- Findings of palpable mass or imaging abnormality (increase in size or in the amount of calcifications) in the observation period will be subject to biopsy; pathology results indicating in situ or invasive disease will prompt multi-disciplinary treatment consistent with established standards of care.Patients in the close observation group will be assessed at six months and annually thereafter with clinical examination and breast imaging. Patients in the surgery group will be followed with yearly clinical breast exam and yearly breast imaging.
Secondary outcomes (1)
- measure
- Quality of life, patient satisfaction and costs between the two groups will be measured by the Functional Assessment of Chronic Illness Therapy (FACIT), specifically the FACT-G and the FACT-Es.
- timeFrame
- 5 years
- description
- The FACT-GP will measure physical well-being, social/family well-being, emotional well-being and functional well-being. Higher scores indicate better well-being. The FACT-Es will be used to assess symptoms related to menopause and tamoxifen or exemestane, as we anticipate many of the subjects will be on endocrine therapy as part of their chemo-prevention.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria A patient/subject is eligible for enrollment if all of the following inclusion criteria are met: 1. Pre- and post-menopausal women ≥ 40 years of age with newly diagnosed ADH, histologically confirmed on breast core biopsy. 2. Ability to understand and the willingness to sign a written informed consent document. 3. Willing to schedule definitive resection of ADH if randomized to surgical excision arm or be observed if randomized to the observation arm. 4. Original breast core biopsy specimen available for pathologic review and staining by Yale School of Medicine Department of Pathology. Exclusion Criteria A patient/subject will not be eligible for this study if any of the following exclusion criteria are met: 1. Patients with a current breast cancer diagnosis or a personal history of cancer 2. Patients with a personal history of an identifiable genetic mutation (BRCA) for breast cancer and, untested first degree relatives of mutation carriers 3. Patients who have previously or are currently taking tamoxifen or exemestane or other chemotherapy or biologic therapy (e.g. trastuzumab) 4. Patients with a history of radiation therapy to the chest wall 5. Pregnant and/or lactating women within past 6 months.
References
Publications (0)
Data not yet available
No reference posted for this study.